The hemostatic role of factor XI.

摘要: Coagulation factor (F)XI has been described as a component of the early phase contact pathway blood coagulation, acting downstream XII. However, patients deficient in upstream members pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient sometimes experience mild bleeding, suggesting FXI plays role hemostasis independent pathway. Further complicating picture, risk is difficult to predict because symptoms have found correlate with antigen levels or activity. recent studies emerged expand our understanding FXI, demonstrating that activated able activate coagulation factors FX, FV, FVIII, inhibit anti-coagulant tissue inhibitor (TFPI). Understanding these activities may help better diagnose which are at for bleeding. In contrast its hemostatic activities, known play significant thrombosis, it demonstrated deep vein ischemic stroke, myocardial infarction. Recent translational approaches begun testing an antithrombotic, one promising clinical study showing anti-sense oligonucleotide against prevented venous thrombosis elective knee surgery. A varied complex both will allow prediction also informing development targeted agents thrombotic preserving hemostasis.